Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula is a phase 3, randomised interventional study registered as NCT06807437 by SWOG Cancer Research Network, with a registry enrolment figure of 274 participants, started 2025-05-09 and due to reach its primary completion in 2027-11-01. Interventions recorded: Biospecimen Collection; Distal Pancreatectomy; Lanreotide; Questionnaire Administration; Saline. Conditions listed: Pancreatic Carcinoma; Pancreatic Neoplasm. Primary outcome: Incidence of postoperative pancreatic fistula (POPF). Pancreatic eligibility wording from the registry: "* Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential". Sites: United States. No results are recorded here; the registry entry is the source.